NCT03301168 - Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 11, 2021

Study Completion Date

May 31, 2034

Conditions

Acute Lymphoblastic LeukemiaLeukemia, Acute Myeloid (AML), ChildLymphoma, Non-HodgkinMyelodysplastic SyndromesPrimary Immune Deficiency DisorderOsteopetrosisCytopeniaHemoglobinopathy in ChildrenAnemia, Aplastic

Interventions

BIOLOGICAL

BPX-501 T cells

T cells transduced with CaspaCIDe® safety switch

DRUG

Rimiducid

administered to inactivate BPX-501 cells in the event of GVHD

Trial Locations (10)

10467

Children's Hospital at Montefiore, The Bronx

20010

Children's National Medical Center, Washington D.C.

30322

Children's Healthcare of Atlanta, Atlanta

77030

Baylor College of Medicine/ Texas Children's Hospital, Houston

77390

University of Texas Southwestern-Children's Medical Center, Dallas

90027

Children's Hospital Los Angeles, Los Angeles

94304

Stanford University - Division of Pediatric Stem Cell Transplant & Regenerative Medicine, Palo Alto

97239

Oregon Health Sciences University - Doernbecher Children's Hospital, Portland

98109

Fred Hutchinson Cancer Research Center, Seattle

02215

Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston